Volume 22 - Issue 9 - September 2014
Department
Allergen Focus
09/17/2014
Recently with the surging advance of portable electronics and mobile devices, cobalt is becoming more frequently used.
Recently with the surging advance of portable electronics and mobile devices, cobalt is becoming more frequently used.
Recently with the surging...
09/17/2014
The Dermatologist
Board Review
09/17/2014
1. Which of the following reduces this condition during wound healing?
1. Which of the following reduces this condition during wound healing?
1. Which of the following...
09/17/2014
The Dermatologist
Research in Review
09/17/2014
Twenty-five years ago rosacea was considered a rare disease.
Twenty-five years ago rosacea was considered a rare disease.
Twenty-five years ago rosacea...
09/17/2014
The Dermatologist
Column
Spotlight
09/17/2014
Dr. Suzanne Connolly completed her medical degree at the University of California, San Francisco.
Dr. Suzanne Connolly completed her medical degree at the University of California, San Francisco.
Dr. Suzanne Connolly completed...
09/17/2014
The Dermatologist
Industry News
09/17/2014
The FDA approved Erivedge (vismodegib) in January 2012 as a first-in-class hedgehog pathway inhibitor indicated for the treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC that has recurred following...
The FDA approved Erivedge (vismodegib) in January 2012 as a first-in-class hedgehog pathway inhibitor indicated for the treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC that has recurred following...
The FDA approved Erivedge...
09/17/2014
The Dermatologist
News
News
09/17/2014
Investigational medicine ixekizumab (Eli Lilly and Company) was statistically superior to etanercept (Enbrel, Amgen Inc.) and placebo on all skin clearance measures in Phase III studies, according to the company.
Investigational medicine ixekizumab (Eli Lilly and Company) was statistically superior to etanercept (Enbrel, Amgen Inc.) and placebo on all skin clearance measures in Phase III studies, according to the company.
Investigational medicine...
09/17/2014
The Dermatologist
09/17/2014
Tensage Serum SCA 15 Biorepair Index from Biopelle, Inc. is a new animal-based growth factor for aging and photodamaged skin.
Tensage Serum SCA 15 Biorepair Index from Biopelle, Inc. is a new animal-based growth factor for aging and photodamaged skin.
Tensage Serum SCA 15 Biorepair...
09/17/2014
The Dermatologist
